The TB Modelling Group and TB Centre at London School of Hygiene and Tropical Medicine have just published findings in Vaccine showing that the M72/AS01E vaccine candidate or BCG-revaccination could be cost-effective in reducing the tuberculosis burden in South Africa. The research team used an age-stratified transmission model of tuberculosis, calibrated to epidemiological data from South Africa, to estimate the potential health and economic impact of M72/AS01E vaccination and BCG-revaccination.
The results showed that M72/AS01E vaccination may have a larger impact than BCG-revaccination, averting approximately 80% more cases and deaths by 2050. Both vaccines were found to be cost-effective or cost saving (compared to no new vaccine) across a range of vaccine characteristics and delivery strategies from both the health system and societal perspective.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.